がん支持療法薬市場：治療クラス別、用途別-2023-2030年の世界予測

がん支持療法薬の世界市場は、2023年に206億2,000万米ドル、CAGR 4.43%で大きく成長し、2030年には280億6,000万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界のがん支持療法薬市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.がん支持療法薬の世界市場規模および予測は？

2.予測期間中、世界のがん支持療法薬市場を形成するCOVID-19の阻害要因と影響は？

3.がん支持療法薬の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.がん支持療法薬の世界市場における競争戦略は？

5.がん支持療法薬の世界市場における技術動向と規制の枠組みは？

6.がん支持療法薬の世界市場における主要ベンダーの市場シェアは？

7.がん支持療法薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高齢者人口の増加に伴うがん罹患率の上昇
    • 新製品の承認と発売の増加
    • がん支持療法薬開発のための研究開発活動の増加
  • 抑制要因
    • がん支持療法薬のコストが高い
  • 機会
    • がん治療のための新しい標的療法の開発
    • バイオシミラーの採用の増加とヘルスケアへの政府支出の増加
  • 課題
    • 薬の摂取に伴う副作用
• 市場動向
• COVID-19の累積的な影響
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制の枠組み
• 顧客のカスタマイズ

第6章 がん支持療法薬市場セラピークラス別

• 非ステロイド性抗炎症薬
• 制吐薬
• ビスホスホネート
• 赤血球生成刺激剤
• 顆粒球コロニー刺激因子
• オピオイド

第7章 がん支持療法薬市場：用途別

• 乳がん
• 結腸直腸がん
• 肝臓がん
• 肺がん
• 前立腺がん
• 胃がん

第8章 南北アメリカのがん支持療法薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域のがん支持療法薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカのがん支持療法薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• FPNVポジショニングマトリクス
• 市場シェア分析：主要企業別
• 競合シナリオ分析：主要企業別

第12章 掲載企業一覧

第13章 付録

• ディスカッションガイド
• ライセンスと価格について

LIST OF FIGURES

• FIGURE 1. CANCER SUPPORTIVE CARE DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2022 VS 2030
• FIGURE 3. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2022 VS 2030 (%)
• FIGURE 5. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
• FIGURE 6. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
• FIGURE 7. CANCER SUPPORTIVE CARE DRUGS MARKET DYNAMICS
• FIGURE 8. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 9. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 11. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 12. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 13. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
• FIGURE 14. CANCER SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• FIGURE 15. CANCER SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

• TABLE 1. CANCER SUPPORTIVE CARE DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
• TABLE 3. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 5. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS , BY REGION, 2018-2030 (USD MILLION)
• TABLE 6. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 7. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 8. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GRANULOCYTE-COLONY STIMULATING FACTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 12. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 23. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 24. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 26. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 27. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 28. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 30. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 31. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 34. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. AUSTRALIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 36. AUSTRALIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. CHINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 38. CHINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. INDIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 40. INDIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. INDONESIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 42. INDONESIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. JAPAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 44. JAPAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. MALAYSIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 46. MALAYSIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. PHILIPPINES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 48. PHILIPPINES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. SINGAPORE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 50. SINGAPORE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 52. SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. TAIWAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 54. TAIWAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. THAILAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 56. THAILAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. VIETNAM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 58. VIETNAM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 59. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 60. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 61. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 62. DENMARK CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 63. DENMARK CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. EGYPT CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 65. EGYPT CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. FINLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 67. FINLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 69. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 71. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. ISRAEL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 73. ISRAEL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. ITALY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 75. ITALY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. NETHERLANDS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 77. NETHERLANDS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. NIGERIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 79. NIGERIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. NORWAY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 81. NORWAY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. POLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 83. POLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. QATAR CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 85. QATAR CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. RUSSIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 87. RUSSIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 89. SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. SPAIN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 93. SPAIN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. SWEDEN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 95. SWEDEN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. SWITZERLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 97. SWITZERLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. TURKEY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 99. TURKEY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. UNITED ARAB EMIRATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 101. UNITED ARAB EMIRATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
• TABLE 103. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. CANCER SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
• TABLE 105. CANCER SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2022
• TABLE 106. CANCER SUPPORTIVE CARE DRUGS MARKET LICENSE & PRICING

The Global Cancer Supportive Care Drugs Market is forecasted to grow significantly, with a projected USD 20.62 billion in 2023 at a CAGR of 4.43% and expected to reach a staggering USD 28.06 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Cancer Supportive Care Drugs Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Cancer Supportive Care Drugs Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Therapeutic Class, market is studied across Non-Steroidal Anti-Inflammatory Drugs, Antiemetics, Bisphosphonates, Erythropoiesis Stimulating Agents, Granulocyte-Colony Stimulating Factors, and Opioids. The Opioids is projected to witness significant market share during forecast period.

Based on Application, market is studied across Breast Cancer, Colorectal Cancer, Liver Cancer, Lung Cancer, Prostate Cancer, and Stomach Cancer. The Liver Cancer is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas is projected to witness significant market share during forecast period.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Cancer Supportive Care Drugs Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Cancer Supportive Care Drugs Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer Supportive Care Drugs Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer Supportive Care Drugs Market?

4. What is the competitive strategic window for opportunities in the Global Cancer Supportive Care Drugs Market?

5. What are the technology trends and regulatory frameworks in the Global Cancer Supportive Care Drugs Market?

6. What is the market share of the leading vendors in the Global Cancer Supportive Care Drugs Market?

7. What modes and strategic moves are considered suitable for entering the Global Cancer Supportive Care Drugs Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Cancer Supportive Care Drugs Market, by Therapeutic Class, 2022 vs 2030
• 4.3. Cancer Supportive Care Drugs Market, by Application, 2022 vs 2030
• 4.4. Cancer Supportive Care Drugs Market, by Region, 2022 vs 2030

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of cancer coupled with increase in the geriatric population
    • 5.1.1.2. Increasing approval and launch of new products
    • 5.1.1.3. Increase in R&D activities for development of cancer supportive care drugs
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of cancer supportive care drugs
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of novel targeted therapies for the treatment of cancer
    • 5.1.3.2. Rising adoption of biosimilar and increasing government expenditure on healthcare
  • 5.1.4. Challenges
    • 5.1.4.1. Side effects associated with consumption of drugs
• 5.2. Market Trends
• 5.3. Cumulative Impact of COVID-19
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework
• 5.9. Client Customization

6. Cancer Supportive Care Drugs Market, by Therapeutic Class

• 6.1. Introduction
• 6.2. Non-Steroidal Anti-Inflammatory Drugs
• 6.3. Antiemetics
• 6.4. Bisphosphonates
• 6.5. Erythropoiesis Stimulating Agents
• 6.6. Granulocyte-Colony Stimulating Factors
• 6.7. Opioids

7. Cancer Supportive Care Drugs Market, by Application

• 7.1. Introduction
• 7.2. Breast Cancer
• 7.3. Colorectal Cancer
• 7.4. Liver Cancer
• 7.5. Lung Cancer
• 7.6. Prostate Cancer
• 7.7. Stomach Cancer

8. Americas Cancer Supportive Care Drugs Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Cancer Supportive Care Drugs Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Cancer Supportive Care Drugs Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
• 11.2. Market Share Analysis, By Key Player
• 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing